Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Molecular mechanism of HIV blockade by a novel antiviral chemokine, XCL1.

EF 2012-13

Résumé
Although many milestones have been reached in understanding interactions between HIV and host immune cells, major gaps remain in our knowledge of how immune cells can control HIV. Key players in the immune response to HIV infection are CD8+ T cells. Although these cells are commonly known to be antiviral by inducing death of infected immune cells, they can also secrete soluble factors known as chemokines, which can suppress HIV directly. Previous research described the production of chemokines by CD8+ T cells as the main drivers of CD8-derived anti-HIV activity. This discovery created a long-lasting impact on the understanding of AIDS pathogenesis, and led to the development of a novel drug therapy for HIV infection, based on the HIV suppressive activity of the newly discovered chemokines. Interestingly, recent evidence indicates the presence of additional, undefined, chemokines produced by CD8+ T cells that can significantly suppress HIV infection. Thus, the purpose of my study is to define the anti-HIV activity of a new CD8+ T cell-derived chemokine, namely XCL1. My research will describe how XCL1 can block HIV infection. More specifically, experiments will show at what stage of the HIV life cycle it is that XCL1 exerts its inhibitory effects. Therefore, this study could be a critical first step in the development of new drugs and therapeutic strategies aimed at controlling HIV infection. Furthermore, strategies to induce production of XCL1 in human hosts could be considered in future HIV vaccine designs.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Maryland, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
269622
Name
Guzzo Christina R
Region
Maryland
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Molecular mechanism of HIV blockade by a novel antiviral chemokine, XCL1.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Chemokines; Elisa; Flow Cytometry; Hiv Attachment; Hiv Drug Therapy; Hiv Infection; Hiv Suppression; Neutralizing Antibodies; Real Time Pcr; T Cells
Abstract
Although many milestones have been reached in understanding interactions between HIV and host immune cells, major gaps remain in our knowledge of how immune cells can control HIV. Key players in the immune response to HIV infection are CD8+ T cells. Although these cells are commonly known to be antiviral by inducing death of infected immune cells, they can also secrete soluble factors known as chemokines, which can suppress HIV directly. Previous research described the production of chemokines by CD8+ T cells as the main drivers of CD8-derived anti-HIV activity. This discovery created a long-lasting impact on the understanding of AIDS pathogenesis, and led to the development of a novel drug therapy for HIV infection, based on the HIV suppressive activity of the newly discovered chemokines. Interestingly, recent evidence indicates the presence of additional, undefined, chemokines produced by CD8+ T cells that can significantly suppress HIV infection. Thus, the purpose of my study is to define the anti-HIV activity of a new CD8+ T cell-derived chemokine, namely XCL1. My research will describe how XCL1 can block HIV infection. More specifically, experiments will show at what stage of the HIV life cycle it is that XCL1 exerts its inhibitory effects. Therefore, this study could be a critical first step in the development of new drugs and therapeutic strategies aimed at controlling HIV infection. Furthermore, strategies to induce production of XCL1 in human hosts could be considered in future HIV vaccine designs.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Guzzo, Christina R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~